Zimmer Biomet Holdings Inc (ZBH) : Baskin Financial Services scooped up 320 additional shares in Zimmer Biomet Holdings Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 3, 2016. The investment management firm now holds a total of 95,095 shares of Zimmer Biomet Holdings Inc which is valued at $12,403,241.Zimmer Biomet Holdings Inc makes up approximately 3.36% of Baskin Financial Services’s portfolio.
Other Hedge Funds, Including , Boston Private Wealth reduced its stake in ZBH by selling 16,838 shares or 29.49% in the most recent quarter. The Hedge Fund company now holds 40,265 shares of ZBH which is valued at $5,251,764. Zimmer Biomet Holdings Inc makes up approx 0.21% of Boston Private Wealth’s portfolio.Neville Rodie Shaw Inc reduced its stake in ZBH by selling 550 shares or 6.8% in the most recent quarter. The Hedge Fund company now holds 7,544 shares of ZBH which is valued at $947,300. Zimmer Biomet Holdings Inc makes up approx 0.11% of Neville Rodie Shaw Inc’s portfolio. Cornerstone Investment Partners added ZBH to its portfolio by purchasing 2,875 company shares during the most recent quarter which is valued at $361,014. Zimmer Biomet Holdings Inc makes up approx 0.01% of Cornerstone Investment Partners’s portfolio.Chevy Chase Trust Holdings boosted its stake in ZBH in the latest quarter, The investment management firm added 18,875 additional shares and now holds a total of 171,926 shares of Zimmer Biomet Holdings Inc which is valued at $21,471,838. Zimmer Biomet Holdings Inc makes up approx 0.12% of Chevy Chase Trust Holdings’s portfolio.
Zimmer Biomet Holdings Inc opened for trading at $131.24 and hit $131.83 on the upside on Monday, eventually ending the session at $131.66, with a gain of 0.20% or 0.26 points. The heightened volatility saw the trading volume jump to 7,36,789 shares. Company has a market cap of $26,232 M.
On the company’s financial health, Zimmer Biomet Holdings Inc reported $2.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.97. The company had revenue of $1934.00 million for the quarter, compared to analysts expectations of $1898.18 million. The company’s revenue was up 65.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.58 EPS.
Many Wall Street Analysts have commented on Zimmer Biomet Holdings Inc. Company shares were Reiterated by Needham on Jul 29, 2016 to “Buy”, Firm has raised the Price Target to $ 150 from a previous price target of $143 .Company shares were Reiterated by Needham on Jul 18, 2016 to “Buy”, Firm has raised the Price Target to $ 143 from a previous price target of $134 .Zimmer Biomet Holdings Inc was Initiated by Guggenheim to “Neutral” on Jun 9, 2016.
Zimmer Biomet Holdings Inc. formerly Zimmer Holdings Inc. is a musculoskeletal healthcare company. The Company designs manufactures and markets orthopedic reconstructive products; sports medicine biologics extremities and trauma products; spine bone healing craniomaxillofacial and thoracic products; dental implants and related surgical products. The Company manages its operations through three geographic segments: the Americas comprising principally of the United States and includes other North Central and South American markets; Europe comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers and directly to dental practices and dental laboratories.